Knockout of Zeb2 ameliorates progression of renal tubulointerstitial fibrosis in a mouse model of renal ischemia?reperfusion injury
Knockout of Zeb2 ameliorates progression of renal tubulointerstitial fibrosis in a mouse model of renal ischemia?reperfusion injury
复制标题
Zeb2 敲除可改善肾缺血再灌注损伤小鼠模型中肾小管间质纤维化的进展
DOI:
10.1093/ndt/gfab311
复制
发表时间:
2021
影响因子:
6.1
通讯作者:
Terada Yoshio
中科院分区:
文献类型:
--
作者:
Inotani Satoshi;Taniguchi Yoshinori;Nakamura Keisyun;Nishikawa Hirofumi;Matsumoto Tatsuki;Horino Taro;Fujimoto Shimpei;Sano Shigetoshi;Yanagita Motoko;Terada Yoshio
BackgroundZeb2, a zinc finger E-box-binding homeobox transcription factor, regulates transforming growth factor (TGF)-βsignaling pathway. However, its role in the pathogenesis of acute kidney injury (AKI) and AKI-to-chronic kidney disease (CKD) transition is unclear.MethodsWe evaluated Zeb2 function in a bilateral renal ischemia–reperfusion injury (IRI)-induced AKI model using proximal tubule-specificZeb2conditional knockout (Zeb2-cKO) and wild-type (WT) mice, and in renal biopsy samples.ResultsIn Zeb2-cKO mice, the levels of plasma creatinine and blood urea nitrogen post-IRI were significantly lower than that in WT mice. Immunohistological analysis revealed mild tubular injury, reduced neutrophil infiltration, fewer fibrotic changes and reduced expression of fibrotic proteins [collagen type IV,α-smooth muscle actin (α-SMA), fibronectin and connective tissue growth factor (CTGF)], at 3–14 days post-IRI. Zeb2 expression was upregulated in proximal tubular cells post-IRI in WT mice.Zeb2siRNA transfection reduced TGF-β-stimulated mRNA and protein expression of collagen type IV,α-SMA, fibronectin and CTGF in cultured renal tubular cells. Patients with AKI-to-CKD transition exhibited high Zeb2 expression in renal tubules, as revealed by renal biopsy. Hypoxia and CoCl2-treatment upregulated Zeb2 promoter activity and mRNA and protein expression in cultured renal tubular epithelial cells, suggesting a regulatory role for hypoxia.ConclusionsZeb2 was upregulated in renal tissues in both mice and humans with AKI. Zeb2 regulates fibrotic pathways in the pathogenesis of AKI and AKI-to-CKD transition. Therefore, inhibition of Zeb2 could be a potential therapeutic strategy for AKI.